Nucletron

Hospital La Fe, a clinical collaborator of Nucletron, an Elekta company, is nearing the conclusion of the enrollment phase of a clinical study with the Esteya electronic brachytherapy system for treating skin cancer.

Esteya, an electronic brachytherapy system, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), enabling medical centers in the United States to offer their patients with skin cancer a new treatment option.

Nucletron, an Elekta company, has signed an agreement with the American Brachytherapy Society (ABS) to continue to support the implementation of a residency-level training program in brachytherapy for radiation oncologists and physicists from the United States and other countries.

August 29, 2012 — The ability of magnetic resonance imaging (MRI) to create exquisite images of the body’s soft tissues – and the tumors that arise amid them – is helping physicians at National Cancer Center Singapore (NCCS) to precisely shape brachytherapy doses to cervical tumors, while at the same time avoiding exposure to critical healthy organs and tissues.

In arc therapy, a linear accelerator gantry moves in a continuous arc around the target while delivering radiation dose. Patients have been routinely treated with this technology since the 1980s, when it was put into use for stereotactic radiosurgery (SRS) of the brain. The advantage was that the low-dose region was spread out over a larger amount of healthy brain, reducing treatment toxicity.